Your browser is no longer supported. Please, upgrade your browser.
Biocept, Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own0.02% Shs Outstand13.40M Perf Week-4.69%
Market Cap57.75M Forward P/E- EPS next Y-1.07 Insider Trans0.00% Shs Float13.40M Perf Month-2.83%
Income-17.80M PEG- EPS next Q- Inst Own10.90% Short Float5.78% Perf Quarter-37.39%
Sales27.50M P/S2.10 EPS this Y87.70% Inst Trans14.10% Short Ratio1.78 Perf Half Y-2.83%
Book/sh3.21 P/B1.39 EPS next Y8.50% ROA-49.80% Target Price- Perf Year8.26%
Cash/sh1.11 P/C4.01 EPS next 5Y40.00% ROE-75.90% 52W Range3.46 - 13.00 Perf YTD0.68%
Dividend- P/FCF- EPS past 5Y72.30% ROI-59.00% 52W High-64.36% Beta0.80
Dividend %- Quick Ratio2.50 Sales past 5Y114.10% Gross Margin22.30% 52W Low33.90% ATR0.27
Employees104 Current Ratio2.60 Sales Q/Q927.80% Oper. Margin-56.60% RSI (14)46.96 Volatility4.87% 5.94%
OptionableYes Debt/Eq0.11 EPS Q/Q113.10% Profit Margin-64.90% Rel Volume0.41 Prev Close4.47
ShortableYes LT Debt/Eq0.06 EarningsMay 12 AMC Payout- Avg Volume435.85K Price4.63
Recom2.00 SMA201.28% SMA50-9.04% SMA200-16.87% Volume154,834 Change3.65%
Nov-14-17Reiterated Chardan Capital Markets Buy $2.50 → $1.50
Jun-02-17Initiated Chardan Capital Markets Buy $2.50
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
May-05-21 08:00AM  
Apr-28-21 08:17AM  
Apr-21-21 08:17AM  
Apr-14-21 08:05AM  
Apr-07-21 04:05PM  
Apr-01-21 05:00PM  
Mar-30-21 08:06AM  
Mar-29-21 04:32PM  
Mar-27-21 04:18AM  
Mar-22-21 08:00AM  
Mar-16-21 11:41AM  
Mar-09-21 07:00AM  
Mar-03-21 04:05PM  
Mar-02-21 11:45AM  
Feb-23-21 12:35PM  
Feb-16-21 08:00AM  
Feb-03-21 08:00AM  
Feb-02-21 04:05PM  
Jan-23-21 02:03AM  
Jan-12-21 08:00AM  
Jan-04-21 08:05AM  
Dec-31-20 05:29PM  
Dec-30-20 08:05AM  
Dec-14-20 08:00AM  
Dec-10-20 08:00AM  
Dec-01-20 11:30AM  
Nov-20-20 08:00AM  
Nov-17-20 08:05AM  
Nov-16-20 06:47PM  
Nov-14-20 07:52AM  
Nov-12-20 04:05PM  
Nov-09-20 08:05AM  
Nov-05-20 08:05AM  
Nov-04-20 08:00AM  
Oct-29-20 08:05AM  
Oct-21-20 08:00AM  
Oct-06-20 08:00AM  
Oct-05-20 08:00AM  
Oct-01-20 08:00AM  
Sep-24-20 08:48AM  
Sep-23-20 08:00AM  
Sep-21-20 06:21PM  
Sep-16-20 08:00AM  
Sep-14-20 08:00AM  
Sep-09-20 08:00AM  
Sep-08-20 08:00AM  
Sep-04-20 04:28PM  
Aug-31-20 06:12PM  
Aug-27-20 08:00AM  
Aug-24-20 08:00AM  
Aug-20-20 08:30AM  
Aug-19-20 08:00AM  
Aug-18-20 08:00AM  
Aug-17-20 07:38PM  
Aug-13-20 08:00AM  
Aug-12-20 04:05PM  
Aug-06-20 11:44AM  
Aug-05-20 06:00PM  
Aug-03-20 08:00AM  
Jul-31-20 02:43PM  
Jul-16-20 08:05AM  
Jun-30-20 08:05AM  
Jun-26-20 10:04PM  
Jun-24-20 08:05AM  
Jun-22-20 08:05AM  
Jun-05-20 08:05AM  
May-29-20 08:30AM  
May-20-20 08:05AM  
May-14-20 08:05AM  
May-13-20 04:05PM  
Apr-29-20 08:05AM  
Apr-28-20 08:05AM  
Apr-20-20 08:05AM  
Apr-14-20 09:00AM  
Apr-13-20 09:54AM  
Apr-09-20 07:17PM  
Apr-02-20 08:05AM  
Apr-01-20 07:53PM  
Mar-28-20 08:23AM  
Mar-26-20 08:05AM  
Mar-25-20 04:05PM  
Mar-18-20 08:30AM  
Mar-11-20 09:23AM  
Mar-09-20 08:05AM  
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HALE DAVID FDirectorJun 12Sale0.56604335112Jun 12 09:42 PM
HALE DAVID FDirectorJun 12Sale0.56556309867Jun 12 09:42 PM